VERNON HILLS, Ill.--(BUSINESS WIRE)--Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc. (“Winston”) (OTC PINK: WPHM), a pharmaceutical company focused on developing and commercializing novel pain management therapies, announced that it has received Notice of Compliance (NOC) from the Therapeutics Drug Directorate, Health Canada for its New Drug Submission (NDS) for CIVANEX ™ (zucapsaicin cream 0.075%) for the treatment of the signs and symptoms of osteoarthritis.
